111 related articles for article (PubMed ID: 12494768)
81. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.
Taylor JK; Zhang QQ; Wyatt JR; Dean NM
Nat Biotechnol; 1999 Nov; 17(11):1097-100. PubMed ID: 10545916
[TBL] [Abstract][Full Text] [Related]
82. Splicing and dicing apoptosis genes.
Reed JC
Nat Biotechnol; 1999 Nov; 17(11):1064-5. PubMed ID: 10545908
[No Abstract] [Full Text] [Related]
83. Reduction of c-myc expression by an antisense approach under Cre/loxP switching induces apoptosis in human liver cancer cells.
Ebinuma H; Saito H; Kosuga M; Wakabayashi K; Saito Y; Takagi T; Nakamoto N; Okuyama T; Ishii H
J Cell Physiol; 2001 Jul; 188(1):56-66. PubMed ID: 11382922
[TBL] [Abstract][Full Text] [Related]
84. Modulation of alternative splicing by antisense oligonucleotides.
Sazani P; Kole R
Prog Mol Subcell Biol; 2003; 31():217-39. PubMed ID: 12494768
[No Abstract] [Full Text] [Related]
85. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.
Sazani P; Kole R
J Clin Invest; 2003 Aug; 112(4):481-6. PubMed ID: 12925686
[TBL] [Abstract][Full Text] [Related]
86. RNA modulation, repair and remodeling by splice switching oligonucleotides.
Kole R; Williams T; Cohen L
Acta Biochim Pol; 2004; 51(2):373-8. PubMed ID: 15218534
[TBL] [Abstract][Full Text] [Related]
87. Antisense effects in the cell nucleus: modification of splicing.
Kole R; Sazani P
Curr Opin Mol Ther; 2001 Jun; 3(3):229-34. PubMed ID: 11497345
[TBL] [Abstract][Full Text] [Related]
88. Antisense-mediated redirection of mRNA splicing.
Vacek M; Sazani P; Kole R
Cell Mol Life Sci; 2003 May; 60(5):825-33. PubMed ID: 12827272
[TBL] [Abstract][Full Text] [Related]
89. [Suppression of expression of bcl-2 and bcl-xL genes using antisense oligonucleotides: a new approach to cancer therapy].
Lebedeva IV; Staĭn SA
Mol Biol (Mosk); 2000; 34(6):1025-38. PubMed ID: 11186002
[No Abstract] [Full Text] [Related]
90. Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides.
Dias N; Stein CA
Eur J Pharm Biopharm; 2002 Nov; 54(3):263-9. PubMed ID: 12445555
[TBL] [Abstract][Full Text] [Related]
91. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
Mercatante DR; Sazani P; Kole R
Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
[TBL] [Abstract][Full Text] [Related]
92. Antisense oligonucleotides: from design to therapeutic application.
Chan JH; Lim S; Wong WS
Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
[TBL] [Abstract][Full Text] [Related]
93. Antisense approaches in prostate cancer.
Chi KN; Gleave ME
Expert Opin Biol Ther; 2004 Jun; 4(6):927-36. PubMed ID: 15174974
[TBL] [Abstract][Full Text] [Related]
94. RNA-Mediated Disease Mechanisms in Neurodegenerative Disorders.
Neueder A
J Mol Biol; 2019 Apr; 431(9):1780-1791. PubMed ID: 30597161
[TBL] [Abstract][Full Text] [Related]
95.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
96.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
